Actively Recruiting
Contribution of Anti-platelet Antibodies Identified With MAIPA Assay in the Demonstration of the Auto-immune Character of a Thrombocytopenia at Diagnosis
Led by University Hospital, Bordeaux · Updated on 2026-02-03
225
Participants Needed
1
Research Sites
310 weeks
Total Duration
On this page
Sponsors
U
University Hospital, Bordeaux
Lead Sponsor
M
Ministry for Health and Solidarity, France
Collaborating Sponsor
AI-Summary
What this Trial Is About
Immune thrombocytopenia (ITP) is an autoimmune disease but, paradoxically, and unlike other autoimmune diseases, antiplatelet antibodies are not used either for the diagnosis of the disease or for its prognosis. ITP is a diagnosis of exclusion retained after elimination of other pathologies leading to a thrombocytopenia. No major study has prospectively evaluated the diagnostic value of the presence of anti-platelet antibodies in the etiological investigation of a thrombocytopenia, nor the impact of platelet antibodies on the course of ITP. The gold standard analysis for the determination of platelet antibodies, is the "monoclonal antibody immobilization of platelet antigens" assay (MAIPA), either direct to detect autoantibodies attached to platelets, or indirect to detect circulating antiplatelet antibodies. Therefore, this work aims to study the contribution of the presence of anti-platelet antibodies detected in MAIPA to determine the autoimmune nature of a thrombocytopenia at diagnosis.
CONDITIONS
Official Title
Contribution of Anti-platelet Antibodies Identified With MAIPA Assay in the Demonstration of the Auto-immune Character of a Thrombocytopenia at Diagnosis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patient over 18 years old
- Thrombocytopenia with platelet count below 100 G/L confirmed twice
- False thrombocytopenia and acute leukemia ruled out
- No treatment started for thrombocytopenia
- Signed informed consent obtained before any study procedures
- Affiliated with or benefiting from a social security scheme
You will not qualify if you...
- Secondary immune thrombocytopenia
- False thrombocytopenia
- Platelet transfusion within the past 7 days with efficacy
- Treatment for thrombocytopenia started (except up to 48 hours of corticosteroid therapy)
- Acute leukemia
- Pregnant or breastfeeding women
- Under legal protection such as guardianship or curatorship
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
CHU de Bordeaux - service de médecine interne
Pessac, France
Actively Recruiting
Research Team
J
Jean-François VIALLARD, Prof
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here